4.1 Article

Impaired Vascular KATP Function Attenuates Exercise Capacity in Obese Zucker Rats

Journal

MICROCIRCULATION
Volume 20, Issue 7, Pages 662-669

Publisher

WILEY
DOI: 10.1111/micc.12065

Keywords

obese; vascular; NADPH oxidase; superoxide; K-ATP channels

Funding

  1. NIH [HL-89581, HL-51971]
  2. AHA [12POST12060126, T32 HL-105324]

Ask authors/readers for more resources

ObjectiveObese subjects exhibit decreased exercise capacity (VO2max). We have shown that vascular K-ATP channel mediates arteriolar dilation to muscle contraction. We hypothesize that exercise capacity is decreased in obesity due to impaired vascular K-ATP function. MethodsThe VO2max was measured in LZR and OZR by treadmill running before and following treatment with the K-ATP blocker glibenclamide i.p. One week later, the spinotrapezius muscle was prepared for in vivo microscopy. Arcade arteriolar diameters were measured following muscle contraction or application of the K-ATP opener cromakalim before and after glibenclamide application. In additional animals, LZR and OZR were treated with apocynin for five weeks. VO2max and arteriolar dilation experiments were repeated. ResultsThe OZR exhibited decreased VO2max, functional and cromakalim-induced vasodilation as compared with LZR. Glibenclamide had no effect on VO2max and functional vasodilation in OZR, but significantly inhibited responses in LZR. Vascular superoxide levels and NADPH oxidase activity were increased in OZR, but reduced in apocynin-treated OZR. Apocynin increased the VO2max, functional and cromakalim-induced vasodilation in OZR with no effect in LZR. ConclusionsExercise capacity is dependent on vascular K-ATP channel function. The reduced exercise capacity in OZR appears to be due in part to superoxide-mediated impairment in vascular K-ATP function.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biology

Simulating a virtual population's sensitivity to salt and uninephrectomy

John S. Clemmer, Robert L. Hester, W. Andrew Pruett

INTERFACE FOCUS (2018)

Article Cardiac & Cardiovascular Systems

Role of the heart in blood pressure lowering during chronic baroreflex activation: insight from an in silico analysis

John S. Clemmer, W. Andrew Pruett, Robert L. Hester, Radu Iliescu, Thomas E. Lohmeierl

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2018)

Article Anesthesiology

Validating the Physiologic Model HumMod as a Substitute for Clinical Trials Involving Acute Normovolemic Hemodilution

Charles R. Sims, Luis R. Delima, Arthur Calimaran, Robert Hester, W. Andrew Pruett

ANESTHESIA AND ANALGESIA (2018)

Article Physiology

Early treatment with GLP-1 after severe trauma preserves renal function in obese Zucker rats

Lusha Xiang, Michael S. Thompson, John S. Clemmer, Peter N. Mittwede, Tazim Khan, Robert L. Hester

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2019)

Article Endocrinology & Metabolism

Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females

John S. Clemmer, Jessica L. Faulkner, Alex J. Mullen, Kenneth R. Butler, Robert L. Hester

BIOLOGY OF SEX DIFFERENCES (2019)

Article Cardiac & Cardiovascular Systems

Preeminent role of the cardiorenal axis in the antihypertensive response to an arteriovenous fistula: an in silico analysis

John S. Clemmer, W. Andrew Pruett, Robert L. Hester, Thomas E. Lohmeier

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)

Article Multidisciplinary Sciences

In silico trial of baroreflex activation therapy for the treatment of obesity-induced hypertension

John S. Clemmer, W. Andrew Pruett, Robert L. Hester

Summary: Clinical trials are ongoing to evaluate the effectiveness of chronic electrical stimulation of the carotid baroreflex for treating hypertension. Mathematical modeling using the HumMod simulator suggests that modulation of renal sympathetic nerve activity and atrial natriuretic peptide secretion are key factors contributing to blood pressure lowering during baroreflex activation therapy in obese hypertensive individuals.

PLOS ONE (2021)

Article Cardiac & Cardiovascular Systems

Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy

John S. Clemmer, W. Andrew Pruett

Summary: Heart failure is a leading cause of death and its prevalence is increasing. Therapies that have been effective in reducing mortality in heart failure with reduced ejection fraction (HFrEF) have not shown the same benefit in heart failure with preserved ejection fraction (HFpEF). This study used a physiology model to simulate HFpEF and predict the effects of baroreflex activation therapy. The results suggest that the suppression of renal sympathetic nerve activity could be a primary determinant of the cardioprotective effects from baroreflex activation in HFpEF.

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction

John S. Clemmer, Taylor J. Ward, Seth T. Lirette

Summary: Heart failure is a major cause of cardiovascular morbidity and mortality, with HFpEF accounting for half of all cases. HFpEF patients are typically older, female, and often have CKD. While drugs have shown benefits in HFrEF, their effects on HFpEF are unclear. Recent studies have found that SGLT2 inhibitors can reduce cardiovascular morbidity and mortality in HFrEF patients. This study aimed to investigate the impact of SGLT2 inhibitors on mortality and end stage renal disease in HFpEF patients.

ESC HEART FAILURE (2023)

Article Physiology

Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling

Kyle H. Moore, John S. Clemmer

Summary: The translation discusses the potential exacerbation of glomerular hypertension in hypertensive CKD patients by DHP CCBs, while suggesting the value of T/L-type CCBs in the treatment of proteinuric renal disease.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2021)

No Data Available